HAL-01 Cells
General information
Description | This cell line was established in 1990 from the peripheral blood of a 17-year-old female with acute lymphoblastic leukemia (ALL-L2). The cell line contains the fusion gene of t(17. 19)(q22. p13) TCF3-HLF (E2A-HLF). |
---|---|
Organism | Human |
Tissue | B Cell Precursor Leukemia |
Synonyms | HAL01, HAL-1 |
Characteristics
Age | 17 years |
---|---|
Gender | Female |
Morphology | Lymphoblast |
Growth properties | Suspension |
Identifiers / Biosafety / Citation
Citation | HAL-01 (Cytion catalog number 305140) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Handling
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Doubling time | 48 hours |
Subculturing | Gently homogenize the cell suspension in the flask by pipetting up and down, then take a representative sample to determine the cell density per ml. Dilute the suspension to achieve a cell concentration of 1 x 10^5 cells/ml with fresh culture medium, and aliquot the adjusted suspension into new flasks for further cultivation. |
Split ratio | 1: 2 to 1: 3 |
Fluid renewal | 2 to 3 times per week |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,x
CSF1PO: 11,12
D13S317: 11
D16S539: 9,11
D5S818: 12,13
D7S820: 10,12
TH01: 6,8
TPOX: 8,11
vWA: 16,17
D3S1358: 15
D21S11: 29,33.2
D18S51: 13,14
Penta E: 11,17
Penta D: 9,10
D8S1179: 13,15
FGA: 20,22
D6S1043: 19
D2S1338: 18,24
D12S391: 18,21
D19S433: 12,13.2
|